MRI and C-11-methyl-L-methionine PET Differentiate Bevacizumab True Responders After Initiating Therapy for Recurrent Glioblastoma

Beppu Takaaki; Terasaki Kazunori; Sasaki Toshiaki; Sato Yuichi; Tomabechi Makiko; Kato Kenichi; Sasaki Makoto; Ogasawara Kuniaki

首页> 外文期刊>Clinical nuclear medicine >MRI and C-11-methyl-L-methionine PET Differentiate Bevacizumab True Responders After Initiating Therapy for Recurrent Glioblastoma

【24h】

MRI and C-11-methyl-L-methionine PET Differentiate Bevacizumab True Responders After Initiating Therapy for Recurrent Glioblastoma

机译：开始复发性胶质母细胞瘤治疗后，MRI和C-11-甲基-L-蛋氨酸PET区分贝伐单抗的真正反应者

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose: Normalization of tumor vasculature after administering bevacizumab (BEV) makes assessment of therapeutic response using MRI difficult. The aim of this study was to clarify whether PET with C-11-methyl-L-methionine (MET-PET) would supplement MRI assessing of response after initiating BEV in glioblastoma.

机译：目的：服用贝伐单抗（BEV）后肿瘤血管系统正常化使得使用MRI评估治疗反应变得困难。这项研究的目的是阐明在成胶质细胞瘤中启动BEV后，带有C-11-甲基-L-蛋氨酸（PET-PET）的PET是否会补充MRI的反应评估。

著录项

来源
《Clinical nuclear medicine》 |2016年第11期|共6页
作者
Beppu Takaaki; Terasaki Kazunori; Sasaki Toshiaki; Sato Yuichi; Tomabechi Makiko; Kato Kenichi; Sasaki Makoto; Ogasawara Kuniaki;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类放射医学;
关键词
C-11-methionine PET; bevacizumab; glioblastoma; MRI; therapeutic response;

机译：C-11-蛋氨酸PET;贝伐单抗;胶质母细胞瘤;MRI;治疗反应;

相似文献

外文文献
中文文献
专利

1. MRI and C-11-methyl-L-methionine PET Differentiate Bevacizumab True Responders After Initiating Therapy for Recurrent Glioblastoma [J] . Beppu Takaaki, Terasaki Kazunori, Sasaki Toshiaki, Clinical nuclear medicine . 2016,第11期

机译：开始复发性胶质母细胞瘤治疗后，MRI和C-11-甲基-L-蛋氨酸PET区分贝伐单抗的真正反应者
2. Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients [J] . Thomas Urup, Line M?rsk Staunstrup, Signe Regner Michaelsen, BMC Cancer . 2017,第1期

机译：贝伐单抗联合治疗在反应性和非反应性复发性胶质母细胞瘤患者中引起的转录变化
3. TRANSCRIPTIONAL CHANGES INDUCED BY BEVACIZUMAB COMBINATION THERAPY IN RESPONDING AND NON-RESPONDING RECURRENT GLIOBLASTOMA PATIENTS [J] . Urup T., Staunstrup L., Michaelsen S., Neuro-Oncology . 2016,第suppla4期

机译：贝伐单抗联合治疗对应答性和非应答性复发性胶质母细胞瘤患者的转录变化
4. Differentiation of Recurrent Glioblastoma from Radiation Necrosis Using Diffusion Radiomics: Machine Learning Model Development and External Validation [C] . Yae Won Park, Ji Eun Park, Sung Soo Ahn, International Conference on Medical Image Computing and Computer-Assisted Intervention;International Workshop on Machine Learning in Clinical Neuroimaging;Radiomics and Radiogenomics in Neuro-oncology using AI Conference . 2020

机译：使用扩散辐射测定的辐射坏死的复发性胶质母细胞瘤的分化：机器学习模型开发和外部验证
5. Writing the true self: Case studies of ENG 101 students responding to a Peter Elbow-inspired curriculum. [D] . Stansell, Jon W. 2012

机译：编写真实的自我：ENG 101学生的案例研究，以彼得·艾伯（Peter Elbow）为灵感的课程。
6. Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients [O] . Thomas Urup, Line Mærsk Staunstrup, Signe Regner Michaelsen, 2017

机译：贝伐单抗联合治疗在反应性和非反应性复发性胶质母细胞瘤患者中引起的转录变化
7. Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients [O] . Urup Thomas, Staunstrup Line Maersk, Michaelsen Signe Regner, 2017

机译：贝伐单抗联合治疗在应答和无应答的复发性胶质母细胞瘤患者中诱导的转录变化

MRI and C-11-methyl-L-methionine PET Differentiate Bevacizumab True Responders After Initiating Therapy for Recurrent Glioblastoma

摘要

著录项

相似文献

相关主题

期刊订阅